Hjem › Autoimmune sygdomme › Illinois
Autoimmune sygdomme kliniske forsøg i Illinois
14 studier for Autoimmune sygdomme søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Willow Rheumatology Wellness, Willowbrook
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07621809A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
RekruttererFase 2
Alder 16 til 70 · Alle køn · Opdateret 17. sep. 2026 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
RekruttererFase 2/3
Alder 6 til 75 · Alle køn · Opdateret 17. sep. 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Chicago, Department of Medicine: Rheumatology, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07103746A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 til 65 · Alle køn · Opdateret 26. aug. 2026 · NCT06121297A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
- University of Illinois Hospital & Health Sciences System, Chicago
RekruttererFase 1/2
Alder 35 til 70 · Alle køn · Opdateret 21. aug. 2026 · NCT06575426RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RekruttererFase 2/3
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Northwestern Memorial Hospital, Chicago
RekruttererFase 1/2
Alder 18 til 70 · Alle køn · Opdateret 13. aug. 2026 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1054, Schaumburg
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 30. jul. 2026 · NCT07039916A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- og 3 flere
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Northwestern University, Chicago
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 30. jun. 2026 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Northwestern University, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. maj 2026 · NCT04422912The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- University of Chicago Medical Center, Chicago
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 4. mar. 2026 · NCT01280825Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.